{"filing":{"accession_number":"0000885590-26-000089","cik":"0000885590","ticker":"BHC","company_name":"Bausch Health Companies Inc.","form":"8-K","filing_date":"2026-07-01","report_date":null,"primary_document":"bhc-20260626.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/885590/000088559026000089/bhc-20260626.htm"},"events":[{"id":15534,"run_id":13857,"accession_number":"0000885590-26-000089","anchor_item_number":"5.02","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Michael Goettler resigned from Bausch Health's Board of Directors effective June 30, 2026, in connection with his appointment as President and Chief Executive Officer of Knoa Pharma LLC.","company_name":"Bausch Health Companies Inc.","ticker":"BHC","filing_date":"2026-07-01","form":"8-K","submitted_at":null,"items":[{"id":13356,"accession_number":"0000885590-26-000089","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Michael Goettler resigned from Bausch Health's Board of Directors effective June 30, 2026, in connection with his appointment as President and Chief Executive Officer of Knoa Pharma LLC. The disclosure centers on the departure of a director from the board, making this a clear executive departure event. Board resignations are material to investors as they affect corporate governance and oversight.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T00:04:51.852016+00:00","company_name":"","ticker":null,"filing_date":""},{"id":13357,"accession_number":"0000885590-26-000089","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Michael Goettler resigned from Bausch Health's Board of Directors effective June 30, 2026, in connection with his appointment as President and CEO of another company (Knoa Pharma LLC). The filing explicitly announces his departure from the board, making this a clear executive departure event. Board resignations are material to investors as they affect corporate governance and oversight.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T00:04:51.852016+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":13356,"accession_number":"0000885590-26-000089","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Michael Goettler resigned from Bausch Health's Board of Directors effective June 30, 2026, in connection with his appointment as President and Chief Executive Officer of Knoa Pharma LLC. The disclosure centers on the departure of a director from the board, making this a clear executive departure event. Board resignations are material to investors as they affect corporate governance and oversight.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T00:04:51.852016+00:00","company_name":"Bausch Health Companies Inc.","ticker":"BHC","filing_date":"2026-07-01"},{"id":13357,"accession_number":"0000885590-26-000089","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Michael Goettler resigned from Bausch Health's Board of Directors effective June 30, 2026, in connection with his appointment as President and CEO of another company (Knoa Pharma LLC). The filing explicitly announces his departure from the board, making this a clear executive departure event. Board resignations are material to investors as they affect corporate governance and oversight.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T00:04:51.852016+00:00","company_name":"Bausch Health Companies Inc.","ticker":"BHC","filing_date":"2026-07-01"}]}